MYLAN ACQUIRING BERTEK’s LABELING, TRANSDERMAL MANUFACTURING CAPACITY
Executive Summary
MYLAN ACQUIRING BERTEK's LABELING, TRANSDERMAL MANUFACTURING CAPACITY in exchange for $39 mil. in Mylan common stock, the company announced Jan. 6. The definitive agreement calls for Mylan to acquire the assets of privately held Bertek in exchange for newly issued shares. The deal is expected to close by the end of February, Mylan said. The shares are to be issued within the next five months. St. Albans, Vt.-based Bertek was founded in 1972. The firm initially focused on label manufacturing and has since expanded into plastics, laminating, and transdermal patches. Bertek operates three facilities: in St. Albans and Swanton, Vt., and in Fort Lee, N.J. Bertek's revenues are projected to reach $21.5 mil. in 1993, Mylan said. Bertek uses contract sales reps to market its labeling and related services; the firm has one in-house sales manager for the patch division. Bertek has transdermal patch supply agreements in place, Mylan noted. The generic drug firm first approached Bertek as a potential patch supplier and subsequently offered to purchase the company. "The medical products division of Bertek will provide Mylan with patents, a joint venture, wound care and other related products that will help fill the pipeline for the generic as well as the branded divisions of Mylan," the company said. Specific products and agreements were not disclosed. "This transaction is another significant step in Mylan's long- term plan to become a fully integrated pharmaceutical company," Mylan said. Mylan, known primarily as a generic drug company, has diversified substantially in recent years. In June 1991, the firm acquired Dow B. Hickam and its 70-person detail force specializing in branded wound healing products and other drugs for the long- term care market ("The Pink Sheet" July 1, 1991, p. 11). Mylan also markets the Parkinson's agent Eldepryl (selegiline) through the Somerset joint venture with Bolar and supplies the antihypertensive/diuretic Maxzide to Lederle.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth